T. S. K. Mok Et Al. , "Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC," European Lung Cancer Congress (ELCC) , vol.30, Geneva, Switzerland, pp.38, 2019
Mok, T. S. K. Et Al. 2019. Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC. European Lung Cancer Congress (ELCC) , (Geneva, Switzerland), 38.
Mok, T. S. K., Wu, Y., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., ... de Castro, G.(2019). Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC . European Lung Cancer Congress (ELCC) (pp.38). Geneva, Switzerland
Mok, T. Et Al. "Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC," European Lung Cancer Congress (ELCC), Geneva, Switzerland, 2019
Mok, T. S. Et Al. "Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC." European Lung Cancer Congress (ELCC) , Geneva, Switzerland, pp.38, 2019
Mok, T. S. K. Et Al. (2019) . "Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC." European Lung Cancer Congress (ELCC) , Geneva, Switzerland, p.38.
@conferencepaper{conferencepaper, author={T. S. K. Mok Et Al. }, title={Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC}, congress name={European Lung Cancer Congress (ELCC)}, city={Geneva}, country={Switzerland}, year={2019}, pages={38} }